Table 2.

Ongoing clinical trials hypothetically suitable in the “neo RAS wt” patients according to the specific mutations detected in ctDNA.

Molecular Alteration	On going Clinical Trials
	NCT04495621:MEN16AA With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)
HER-2	NCT03457896: Study of Netatinib + Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAS/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
RET	NCT03037385: Phase1/2 Study of the Highly- selective RET Inhinitor, Pralsetinib (BLU-667), in Particpants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)
IDH1/2	NCT04584008: Targeted Agent Evaluation in Digestive Cancerns in China Based on Molecular Characteristics (VISIONARY)
KIT	NCT04771520: Avapritnib for thr Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
MET	NCT02205398: Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mcRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy